Dermatology

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

Several studies have noted a potential link between methotrexate and an increased risk of skin cancer.

Results from the phase 2 and long-term trials will be presented later this year, following further data collection.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

Soft tissue reconstruction solutions can leverage a patient’s natural healing response.

Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.

Clinical trials show that patients with atopic dermatitis experienced improved symptoms with dupilumab starting at 8 weeks, with maximum effect around 12 weeks.

All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.

Patients with this skin condition must make an ongoing commitment to their therapy regimen for best results.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.

Study data showed that more than three-quarters of patients with dermatomyositis who received intravenous immune globulin therapy experienced improved symptoms.

Prior evidence regarding the safety and efficacy of the combination of apremilast and phototherapy was lacking, prompting researchers to investigate further.

Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Deucravacitinib is a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, which is a member of the Janus kinase (JAK) family.

Alopecia areata is an autoimmune disease with an underlying immuno-inflammatory pathogenesis.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.

Neutrogena On-the-Spot with benzoyl peroxide helps reduce treat acne breakouts.

Triple Paste Ointment is used to treat rashes, including diaper rash.

Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.

Researchers discovered that a common anti-inflammatory drug could lower the number of patients on ventilators from COVID-19, increasing the likelihood of survival by more than 50%.

Guidelines provide information on the management and treatment of this common skin condition.

Campho-Phenique is an antiseptic liquid indicated for the treatment of insect bites, minor skin irritations, and minor burns.

Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Calazime is indicated for the treatment and prevention of diaper rash and minor skin irritations.

Daptomycin for injection (Cubicin) is indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections.